International Health Regulations

Debate between Jim Shannon and Andrew Stephenson

Tuesday 14th May 2024 Commons Chamber

[Andrew Stephenson]

I happily reassure my hon. Friend that national sovereignty comes first. We will continue to do everything that we can to ensure that we get an accord that is agreeable, but if the accord would undermine our sovereignty and our ability to act domestically in any way, we will simply not sign it.

[Jim Shannon (Strangford) (DUP)]

I have been contacted by a large number of constituents who have voiced grave concerns about the powers and rights requested and required by this unelected body. While we may support some of the work carried out to help developing countries, I will not sign away the sovereignty of this nation. Our participation in the WHO should not come with a prerequisite of signing up to these demands. Further, if that is the case, we should no longer be a participating member of the WHO.

Glaucoma and Community Optometry

Debate between Jim Shannon and Andrew Stephenson

Tuesday 30th April 2024 Westminster Hall

[The Minister for Health and Secondary Care (Andrew Stephenson)]

It is always a pleasure to see you in the chair, Dame Caroline. Can I start by thanking the hon. Member for Strangford (Jim Shannon) for raising the importance of eye health to the wellbeing of people across our United Kingdom. No Westminster Hall debate is the same without him. I also thank the hon. Member for East Londonderry (Mr Campbell), and the shadow Minister, the hon. Member for Denton and Reddish (Andrew Gwynne), for their contributions.

Losing one’s eyesight can be devastating. I pay tribute to the charities that have done so much to help people living with glaucoma, or which are researching a cure: Glaucoma UK, the Glaucoma Foundation and the Royal National Institute for Blind People to name just a few. This morning, we are focusing on glaucoma and the role that can be played by community optometry. This afternoon, there will be a debate on the broader issue of preventable sight loss. I am responding to both debates on behalf of my right hon. Friend the Member for South Northamptonshire (Dame Andrea Leadsom), who is the Minister responsible for primary and secondary eye care services. She is otherwise engaged, as she is a member of the Tobacco and Vapes Bill Committee. I know she would want me to put it on the record and reassure Members throughout the House that that remains one of her top priorities.

As I am standing in today, I want to reassure Members that this is a subject close to my own heart. Glaucoma affected several people on my father’s side of the family—my great aunt, Emily Stephenson, lost her eyesight in her 60s because of glaucoma. I remember visiting her as a child and seeing the RNIB talking book cassette tapes, which she loved, and I am delighted that that service continues today in more formats and with more titles than ever before. My mother, too, lives with glaucoma, so I take this issue very seriously.

Up and down the country, community optometry plays an essential role in protecting people’s eye health. It also plays a key role in the early detection of glaucoma, as most glaucoma patients are identified through routine sight tests. Glaucoma cannot be felt—it does not cause any symptoms, and the eye pressure does not cause any pain. That is why regular sight tests are essential, so that problems such as glaucoma can be diagnosed and treated as early as possible.

As the hon. Member for Strangford suggested, everyone should have a sight test every two years. The NHS invests over £500 million every year in providing sight tests and optical vouchers. Between 2022 and 2023, we delivered over 12 million NHS sight tests free of charge. The tests are widely available for millions of people and the budget is entirely demand led, meaning that there is no cap on how many we will provide. We understand that some people may not prioritise sight tests compared with other healthcare, or they might not know that eye tests are recommended every two years. That is why we are always looking for opportunities to remind the public to have a test, through social media and other campaigns. Sight-test providers such as Specsavers and others on the high street display information about NHS sight-test eligibility.

We are committed to making greater use of community optometry to help to alleviate pressures in secondary care. Many integrated care boards are already commissioning a greater range of services on the high street, including minor and urgent eye care services, pre and post-cataract checks, and glaucoma referral filtering and glaucoma monitoring.

Glaucoma referral filtering schemes have delivered fantastic results, with additional tests that double-check whether a patient really needs to be referred to secondary care. These are tried-and-tested schemes that can save patients time and worry while freeing up space for those who most need specialist attention in hospital. Devon is a great example of that. An old Nightingale ward has been repurposed with equipment to screen large numbers of glaucoma and medical retina patients. The diagnostics hub has demolished the hospital’s backlog from just under 4,000 in April 2022 to just below 500 in October 2023—almost a 90% decrease. In Milton Keynes, 70% of suspected glaucoma patients were discharged following refinement of initial referrals made on the high street. About 50% of integrated care boards currently have a version of those schemes in place, and we are assessing the potential for encouraging the roll-out of those schemes even further.

It is vital that patients who need secondary care have access to timely diagnosis and any necessary clinical treatment. The hon. Member for Strangford is right to say that those services suffered during the pandemic, just as they have across the NHS. That is why we have set an ambitious target to recover services through the elective recovery plan, supported by more than £8 billion of dedicated funding, and it is why we have expanded surgical hubs and harnessed the capacity of the independent sector, so that more patients can be seen more quickly. That has been particularly successful for cataract surgery.

Our plan is working and it is delivering results, as waiting times are falling. The number of patients waiting 78 weeks or longer for ophthalmology has been reduced by 96% since its peak, but we know that we have to go further. As well as cutting waiting lists today, we are looking at how we can reform eye care services to meet the demands of tomorrow. NHS England’s transformation programme is running seven projects across each integrated care system area, such as those that test how improving IT links between primary and secondary care could allow patients to be assessed and triaged virtually, saving them time and freeing up more hospital capacity for patients who need specialist face-to-face care the most. NHS England is gathering data and evaluating different interventions, looking to develop a convincing case on what works best and supporting further expansion.

We are going further and faster to free up hospital capacity. Today, many glaucoma patients often have their condition managed in hospital, but in some cases, where clinically appropriate, there is no reason why they cannot be seen somewhere else in their community that is more convenient for them. In England, it is up to ICBs to commission services based on local need, and some ICBs are already trying new ways of working to do just that.

Finally, on research, I want to recognise just how much potential there is for research and innovation to change the lives both of people who suffer from sight loss and of their families. The UK leads the world in research; we could not be more committed to pioneering new treatments and improving our understanding of sight loss. We put our money where our mouth is by awarding the Moorfields Biomedical Research Centre £20 million to carry out another five years of world-leading research in December 2022. Thirteen out of the 100 leaders and innovators in ophthalmology across the world who were included in The Ophthalmologist’s “Power List 2023” were researchers from Moorfields, and we should be proud that that centre of excellence is right here in London.

[Jim Shannon]

I thank the Minister for his very positive and helpful response. The shadow Minister referred to ophthalmology services increasing by 40% over the next 20 years—those figures might not be entirely accurate, but I think that is what he said. That certainly indicates to me that we need to have a progressive and active programme to ensure that people can get tests in partnership with opticians. The Minister mentioned ICBs and how that will be done; I say this respectfully, but can we have some meat on the bones as to how that would work? I am ever mindful that the Minister wants to see that, but we wish to see that as well.

[Andrew Stephenson]

NHS England is looking at a range of different interventions across the country. One of the benefits we have across England, and of course across the United Kingdom, is that we can try different things, such as models of delivery, in different parts of the United Kingdom and learn lessons from one another.

The current strategy pursued by the NHS is to look at different programmes across England and evaluate them to see what delivers the best outcomes for patients. That will help us to improve access for patients and deliver quality treatment. We hope that that evaluation will enable us to suggest best practice. It will still be up to ICBs to commission services—we believe they should be commissioned locally—but we hope that by providing an evidence base for them they can take decisions in the best interests of their local communities. To address the point made by the shadow Minister, that will address the growing demand for services. We recognise the fact that there will be more demand in the years to come. It will also help to address some of the backlogs with which we have struggled since the pandemic.

I hope I have said a few things to convince the hon. Member for Strangford that, while we still have much to learn from Northern Ireland, the Government take glaucoma extremely seriously. Community optometry is helping us manage the flow of glaucoma patients and it is already deployed effectively in many areas across the country to support patients.

We should be under no illusion about how many people watch Parliamentlive.tv. I think it was Stanley Baldwin who once said that the best way to keep a state secret was to announce it on the Floor of the House of Commons. Nevertheless, I wish to end with an appeal to anyone watching this debate at home: remember to take an eye test and please check the NHS website to see whether you are eligible for help. In preparing for today’s debate, I decided to do just that and I will be having my eyes tested tomorrow morning.

Oral Answers to Questions

Debate between Jim Shannon and Andrew Stephenson

Tuesday 23rd April 2024 Commons Chamber

[Andrew Stephenson]

The GMC and other professional regulators have a statutory duty to investigate any concerns about the fitness to practice of one of their registrants and to take appropriate action to protect the public when that is needed. The regulators are overseen by the Professional Standards Authority for Health and Social Care, which has the power to appeal cases where, in its view, a sanction imposed by a regulator is insufficient to protect the public.

[Jim Shannon (Strangford) (DUP)]

The GMC has seven principles of decision making and consent. How will the Minister ensure that GPs can fulfil their obligations when time constraints on appointments mean that they do not have time to listen to every complaint? People have to book a double appointment to talk about more than one issue. What further support can the Government give GPs to enable them to fulfil their GMC-ordered standards of care?

Type 2 Diabetes: Availability of Drugs

Debate between Jim Shannon and Andrew Stephenson

Tuesday 30th January 2024 Westminster Hall

[The Minister for Health and Secondary Care (Andrew Stephenson)]

It is a pleasure to see you in the Chair, Mr Pritchard. I thank the hon. Member for Edinburgh West (Christine Jardine) for raising such an important issue. I want to begin by emphasising that I understand that medicine supply issues are a significant cause of frustration for many of our constituents across the United Kingdom. I also recognise that there have been particular challenges recently with certain medicines. Without diminishing those challenges, it is important that we set them in context.

There are around 1,400 medicines licensed in the UK, most of which are in good supply. The Department is regularly notified of supply issues; thankfully, the vast majority of those can be managed with minimal impact on patients. The medicine supply chain is highly regulated, complex and global, meaning that there can sometimes be supply issues that affect the UK, along with other countries around the world.

There are a number of reasons why a limited number of medicines might be subject to a disruption in supply, such as manufacturing difficulties, regulatory non-compliance, access to raw materials or distribution problems. We cannot always prevent supply issues occurring, but where they do the Department has a range of well-established processes to manage them and help mitigate the risk to patients.

Where there are concerns about supply, they largely, although not exclusively, concern medication to treat the most common conditions. That is exactly the case with what we are talking about today—diabetes—a condition experienced by more than 4.9 million people across the UK. Action on diabetes will be included in the major conditions strategy, as it is an important risk factor for cardiovascular disease. If someone has diabetes, they are twice as likely to have heart disease or a stroke than someone who does not have diabetes, which goes to the heart of what the hon. Member for Edinburgh West said about the importance of ensuring diabetics get their medication.

[Jim Shannon]

I thank the Minister for his comprehensive and helpful response. Some years ago, when I first came to Parliament there was a diabetes strategy for the whole of the United Kingdom of Great Britain and Northern Ireland. If the Minister could look at it, I think a renewal of that particular strategy would help. It was agreed here at Westminster, but took in all the regions of Scotland, Wales and Northern Ireland. It was a marvellous objective to address diabetes and it seemed to work. I would like to see it happen again.

[Andrew Stephenson]

The hon. Member makes an important and powerful point, as usual. As he knows, I am a proud Unionist and am keen for us to do as much as we can in collaboration. I recognise that health is a largely devolved matter. However, since I joined the Department of Health and Social Care in October, I have visited Northern Ireland, Scotland and Wales, I have talked about how we can collaborate more closely on things such as research and innovation, and I am sure that we can do more together where the devolved Governments agree. Last night we had encouraging news. Hopefully we will have power-sharing arrangements back in place in Northern Ireland so that we can work together collaboratively to deliver those benefits for patients.

I will finish the point I was making about the major conditions strategy. That strategy aims primarily to improve care and health outcomes for those living with multiple conditions, and it will be centred on prevention. We have heard from a wide range of stakeholders, whose views are informing the development of the strategy. I will meet Diabetes UK this week to continue that engagement.

With regards to the availability of drugs to treat type 2 diabetes, as the hon. Member for Edinburgh West set out, there has been a significant global supply issue affecting glucagon-like peptide-1 receptor agonists—GLP-1RAs—with the shortages driven by an increase in demand for such products for licensed and off-label indications, meaning that the medicine is being used for a different use from that stated on its licence.

I will set out the steps we have taken to manage those issues. We have continued to work with suppliers to take action to resolve the issues as quickly as possible, including expediting deliveries and boosting supplies. In July last year, we issued guidance for healthcare professionals, which took the form of a national patient safety alert on how to manage patients during the supply disruption. Clinicians and prescribers were directed not to initiate new patients on these medicines, which were to be used only to treat their licensed indication, protecting supplies for diabetic patients. Guidance was supported and echoed in a statement issued by the professional regulators.

One of the particular shortages affecting the market at the moment is Ozempic, which is the brand name for semaglutide, which is licensed to treat type 2 diabetes. Wegovy is the same medicine—semaglutide—but licensed specifically for weight management and is generally used at a higher dose than Ozempic. Obesity-related conditions can be serious, so it is right that we support people living with obesity to lose weight, and Wegovy is one option for those with severe obesity and comorbidities. However, it became available for prescription in the UK only on 4 September 2023, having received approval for use on the NHS for weight management in March 2023.

We believe that supply issues with Ozempic have in part been contributed to by off-label prescribing of that medicine for weight loss ahead of Wegovy’s launch. However, the strong and clear guidance that we provided on the use of those treatments only for their licensed indications and our ongoing work with the industry has helped to protect supplies for diabetic patients.

As a result of our continued intensive work with the supply chain, I am pleased to inform hon. Members that the supply position of that particular drug has improved. Supplies of Rybelsus have been boosted to support demand from new patients with type 2 diabetes, patients switching from Byetta injections and patients switching from Victoza injections. The national patient safety alert was amended on 3 January to reflect that positive development. The professional regulators have issued a second statement to highlight that update.

I am also delighted to highlight the fact that the Medicines and Healthcare Products Regulatory Agency gave regulatory approval in the last few days to Mounjaro, an injectable medicine for adults with type 2 diabetes. That will bring an additional treatment option and will mean that more diabetic patients will have access to the medicines that they need.

Sadly, supply is not expected to return to normal due to the issues with certain products, but we will continue to work with the manufacturers, the NHS, the MHRA and others working in the supply chain, to help ensure that, overall, supplies of GLP-1 RAs are available for patients.

[Jim Shannon]

I think the hon. Members for Edinburgh West (Christine Jardine) and for Wansbeck (Ian Lavery) and I would be interested know about the other option—if I caught you right, Minister—that you mentioned, which is in the form of an injection but is not insulin. Just so we know, is it a different system?

--- Later in debate ---

[Andrew Stephenson]

Sorry, was the hon. Gentleman asking about the approval of the new drug, Mounjaro, which I just mentioned?

[Jim Shannon]

Yes, I am trying to understand, because I am not aware of it, and neither are the hon. Lady or the hon. Gentleman. It is not insulin for type 2, is it? The Minister mentioned an injection system.

[Andrew Stephenson]

It is an injectable medicine for adults with type 2 diabetes. It was recently approved by the MHRA. To put a little bit of extra information out there, the National Institute for Health and Care Excellence recommended Mounjaro, the same drug, for the treatment of patients with type 2 diabetes who meet specific criteria. The NHS in England is therefore now legally required, in line with NICE recommendations, to fund its use for eligible patients. The availability of that new medicine in Scotland is, however, a matter for the devolved Administration. The Scottish Medicines Consortium, which makes decisions on the use of medicines in Scotland, has not yet published guidance on Mounjaro. It will be a matter for the SMC as to whether that becomes an option in Scotland.

As I was saying, Mr Pritchard, unfortunately we expect supply chain issues to continue for the rest of the year. Throughout the management of this issue, our guidance has been supported by additional advice issued in Scotland, Wales and Northern Ireland, which has, critically, reinforced the messaging provided by the national patient safety alerts.

Oral Answers to Questions

Debate between Jim Shannon and Andrew Stephenson

Tuesday 23rd January 2024 Commons Chamber

[Andrew Stephenson]

My right hon. Friend makes an important point. Diagnostic checks are a key part of the cancer pathway and the 150 community diagnostic centres opened by this Government, including the one at the Finchley Memorial Hospital, will provide earlier diagnostic tests, support earlier diagnosis and bring down waiting times, benefiting millions of patients. These centres have delivered more than 6 million additional tests for all elective activity since July 2021 and we expect the Finchley Memorial Hospital CDC to provide over 126,000 tests for elective care in the next financial year.

[Jim Shannon (Strangford) (DUP)]

I thank the Minister for that response. Research and development is very important; it means we can find more cures for cancer. My father, who is dead and gone, survived cancer on three occasions; that happened because of advances in finding cures. What is being done to work alongside those in research and development to ensure that even more cancers can be cured and we can go from a 50% rate to perhaps a 60% or even 70% rate for those who live longer?

[Andrew Stephenson]

I was delighted that one of my first visits in the new year was to Northern Ireland to see some of the life sciences companies, particularly those based around Queen’s University Belfast. That sector in Northern Ireland is flourishing. We are keen to support companies working in research and bring together world-leading universities such as Queen’s with the private sector and the NHS to deliver improved outcomes for all patients across every part of the United Kingdom.

Crohn’s and Colitis Awareness Week

Debate between Jim Shannon and Andrew Stephenson

Tuesday 12th December 2023 Commons Chamber

[The Minister for Health and Secondary Care (Andrew Stephenson)]

Let me start by congratulating the hon. Member for Livingston (Hannah Bardell) on securing this debate on this important issue. She is a tireless campaigner for those living with bowel conditions, particularly Crohn’s and colitis, and she has spoken movingly this evening about her own family’s experience of the condition. I also pay tribute to the hon. Members for Chesham and Amersham (Sarah Green), for Strangford (Jim Shannon), for Upper Bann (Carla Lockhart) and for East Renfrewshire (Kirsten Oswald) for their contributions. I will try to address as many of the points that have been made in the time allowed to me.

It is important that we all do everything we can to break the stigma and ensure that sufferers’ voices are heard. The hon. Member for Livingston has already done invaluable work in helping to re-establish the all-party group on Crohn’s and colitis. I also wish to pay tribute to the charities that support half a million people living with IBD across the UK all year round—Crohn’s and Colitis UK, the Crohn’s in Childhood Research Association, and the Crohn’s and Colitis Foundation, to name just a few. On this issue, as with so many others, it is vital that we do everything we can to break down the barriers to those affected from accessing healthcare. As Crohn’s and Colitis UK has said, “it takes guts” to come forward with your story, and I salute its “cut the crap” campaign. I look forward to working with the hon. Lady as we find solutions to improve the lives of people living with this disease. As she has rightly said, living with Crohn’s and colitis can be a daily struggle. Symptoms of the disease can be embarrassing, leading to people feeling isolated and not reaching out for the support they need.

I will focus briefly on three things my Department and NHS England are doing to help sufferers: raising professional awareness, improving diagnosis and research. I begin with the crucial point about raising awareness, as getting people diagnosed as early as possible is key.

There are two kinds of awareness. First, as the hon. Member for Chesham and Amersham mentioned, there is raising awareness among the public. Stigma is the invisible wall preventing people from seeking the help they need and campaigners are central to smashing that stigma, because of their reach into communities across the country. Campaigners, like the hon. Member for Livingston’s constituent Steven Sharp, have done much to raise awareness and break down that invisible wall. They encourage people to get to their GPs and ask the right questions. I am keen for us to be backing people like Steven every step of the way.

By helping GPs to recognise the symptoms of Crohn’s and colitis through NHS England’s “Getting it right the first time” gastroenterology programme, conditions can be diagnosed as quickly as possible. The programme supports primary care services, driving appropriate referrals and managing inflammatory bowel disease in the community, and is estimated to reduce emergency admissions by more than 6,500 a year. It has been commended by the King’s Fund, which is not always in the habit of showering praise on the Government.

It is also right that doctors should be properly trained to treat the symptoms of Crohn’s and colitis as they appear. In the past five years, the National Institute for Health and Care Excellence has produced a range of guidance to ensure that the care doctors provide for Crohn’s is based on the best possible evidence.

Early diagnosis can make a clear difference to people’s quality of life. We are working hard to improve early diagnosis rates through the “Getting it right the first time” programme and through measures that include more six and seven-day services, extended hours, reviewed and expanded endoscopy capacity, and improved patient flow. NHS England is working closely with front-line clinical experts, patient representatives and leading charities to develop evidence-based tools that improve care. The work includes provision of a right care scenario on inflammatory bowel disease. That will set out our expectations of high-quality, joined-up care at every point of the patient journey, from diagnosis to treatment. Officials assure me this is being finalised and will be delivered in the coming year.

NHS England’s national bladder and bowel health project is delivering better care to people with inflammatory bowel disease, with a focus on developing clinical pathways. Making a diagnosis of Crohn’s and colitis can be difficult and frustrating for patients as the condition can be confused with irritable bowel syndrome, so I am pleased that NICE has recently made faecal calprotectin tests available on the NHS as a non-invasive, inexpensive method for assessing patients before invasive procedures are required.

As the Minister responsible for life sciences, I am passionate that we can do everything we can to accomplish better patient outcomes through investing more in research. That is key to gaining a better understanding of the causes of inflammatory bowel disease, leading to better diagnosis, treatment and outcomes.

[Jim Shannon]

I thank the Minister for his comprehensive response, by which I am sure hon. Members are encouraged. However, the hon. Member for Livingston and I asked specifically about PIPs, which we are very concerned about. I know that is not the Minister’s responsibility, but will he undertake to speak to the relevant Minister to ensure there are movements to help and improve that system?

[Andrew Stephenson]

I am happy to give the hon. Member that undertaking. As he rightly acknowledges, I am not a Department for Work and Pensions Minister. I do not want to tread on their toes, but I will be relaying the clear views expressed during the debate to DWP Ministers because it is important that we get the benefit system right to support all people living with conditions such as these.

I will, if I may, return to the research point. We are investing more than £1 billion a year in health research with the National Institute of Health and Care Research. We are funding 60 projects on Crohn’s and colitis research, backed by more than £33 million over the past five years. I appeal to every scientist who may be interested in research in this area to keep applying for grants through the NIHR. I will leave no stone unturned in finding out what more can be done to address the needs of people affected by these conditions. I look forward to working with the hon. Lady to create the kind of care that people deserve. Whatever our political differences, I am sure that we will agree that half a million people living with inflammatory bowel disease are entitled to the highest possible standards of care and support.

I will continue engaging with the hon. Lady and with NHS England to make sure that the “Getting it right first time” programme is delivering results for patients on the ground. I began this speech by talking about the invisible wall preventing people from accessing the healthcare that they need. Let us tear down that wall together.

Question put and agreed to.

Homes and Buildings: Levelling Up Health and Wellbeing

Debate between Jim Shannon and Andrew Stephenson

Thursday 20th October 2022 Westminster Hall

[The Parliamentary Under-Secretary of State for Levelling Up, Housing and Communities (Andrew Stephenson)]

It is a pleasure to serve under your chairmanship, Mr Hollobone. I congratulate the hon. Member for Strangford (Jim Shannon) on securing this debate and pay tribute to his tireless work and that of the healthy homes and buildings APPG in improving the conditions of those living or working in poor-quality, unhealthy environments.

We can all agree that the past two years have brought into sharp focus just how integral our homes and communities are to our physical and mental wellbeing. It has underscored the imperative of the APPG’s mission to tackle poor-quality housing and our collective endeavour to ensure that everyone in our society lives somewhere decent, warm, safe and secure. That mission is only becoming more pertinent as winter fast approaches and as we act to help people struggling with the rising cost of living. I understand that the Healthy Homes Bill had its Second Reading in July, and today I hope to outline how the Government are already dealing with many of the issues highlighted in that Bill.

Before I turn to levelling up, I pay tribute to the hon. Member for Coventry North West (Taiwo Owatemi) and the shadow Minister, the hon. Member for Luton North (Sarah Owen), for making two excellent speeches. Both their contributions were fantastic. There was very little I would disagree with in either of their speeches. That demonstrates the broad consensus across this House for dealing with the challenges we face.

I want to reiterate the Government’s commitment to levelling up, which remains a key priority for the UK Government. We know that the UK’s economic challenges are hitting some places harder than others. As well as the immediate Government help that we need to therefore provide to those communities, we need to build places up to help them become stronger and more economically resilient. With that in mind, the Government have set out a UK-wide aim to boost our GDP growth.

We recognise that the UK economy is made up of many different local economies with different characteristics, opportunities and challenges. We therefore aim to achieve and sustain strong economic growth by unleashing the untapped potential of places around the UK. That does not mean we want to dampen down the success of London or the growth of the south-east. We want to grow the whole economy, focusing on every part of the country. We want to ensure that we support growing parts of the economy—for example, life sciences in the north-west of England, advanced manufacturing in the midlands, semiconductors in Wales, renewable energy in East Anglia and fintech in Northern Ireland.

It goes without saying that everybody deserves to live in a safe and secure home. As hon. Members know, the decent homes standard has been in place since 2001. It set the minimum standard of quality to be met for all dwellings provided by registered providers of social housing. The decent homes standard sets out four criteria for evaluating decency. It requires that homes are free of serious hazards, are in a reasonable state of repair, have reasonably modern facilities such as kitchens and bathrooms, and have efficient heating and effective insulation to provide a minimum degree of thermal comfort.

The regulator of social housing requires that social rented homes are maintained by landlords to at least the quality set out in the decent homes standard. Good progress has been made on ensuring that social rented sector homes meet the standard, with non-decency in the sector at around 11% in 2020, although I acknowledge the regional disparities in those rates, which was highlighted by the hon. Member for Strangford.

In the aftermath of the Grenfell Tower tragedy, the Department published the social housing Green Paper. During the consultation, we heard that the decent homes standard was no longer fully effective. That is why in the social housing White Paper we committed to review the decent homes standard to ensure that it works for residents and landlords. Part 1 of the DHS review concluded in September 2021 and established that there is a case for change. Further details on taking forward the review will be set out in due course.

The Government are equally committed to ensuring a fair deal for private renters. Over the past two years, we have introduced regulations that will make privately rented homes safer in respect of their electrical installations —again, a point focused on extensively and eloquently by the hon. Member for Strangford—and through the provision of smoke and carbon monoxide alarms.

We have also reviewed the housing health and safety rating system—the tool used to assess conditions in all homes. That will enable local authorities to take more effective, targeted enforcement when they discover health and safety hazards. Last week, our current Prime Minister re-committed to the ban on section 21 no-fault evictions to protect tenants. We are, of course, carefully considering the next steps to support the rental market.

Several hon. Members talked about the importance of energy efficiency and decarbonisation, including the hon. Member for Tiverton and Honiton (Richard Foord) in his intervention. As I said, we will make sure that rented homes are warm and dry. To meet that aim, we will deliver our net zero target, requiring all of our housing stock to become more energy-efficient. My Department is working closely on that with colleagues from the Department for Business, Energy and Industrial Strategy. Improving the energy performance of our buildings presents an opportunity to provide warm, well ventilated spaces and healthy environments in which people can live and work. That will avoid physical illnesses such as heart and lung conditions—again, issues that were spoken about passionately by the hon. Member for Coventry North West and the shadow Minister.

The journey to net zero buildings starts with better energy performance and improving the energy efficiency of homes and buildings. It is a no-regrets action. That is why we are committed to upgrading as many homes as possible to energy performance certificate band C by 2035, as a cost-effective, practical and affordable step. Building on this, we have committed to consider setting a long-term regulatory standard to improve social housing to EPC band C, and we will consult on this in 2023.

Improving the energy efficiency of homes is also the best long-term method of reducing energy costs for vulnerable households and those living in fuel poverty. Our target is to ensure that as many fuel-poor homes as is reasonably practicable achieve a minimum energy rating of band C by 2030. To this end, we are investing £12 billion in Help to Heat schemes to make people’s homes warmer and cheaper to heat. We will deliver upgrades to more than half a million homes in the coming years through our social housing decarbonisation fund, the home upgrade grant scheme and the energy company obligation scheme. To future proof buildings, the heat and building strategy also commits us to considering overheating risk and indoor air quality when developing future decarbonisation policies.

Further to this, from 2025, the future homes standard will ensure that new homes produce at least 75% less CO₂ emissions than those built to the 2013 standards. That represents a considerable improvement in energy efficiency standards for new homes. In December 2021, we introduced an uplift in energy efficiency standards that delivers a meaningful reduction in carbon emissions and provides a stepping stone to the future homes standard in 2025.

Looking towards health and safety, the Building Safety Act 2022 established a more stringent regulatory regime in design and construction, strengthening building regulations requirements and their oversight. The Act introduces a Building Safety Regulator, which will make buildings safer by enforcing a stringent new regulatory regime for high-rise residential and other in-scope buildings. The regulator will oversee the safety and performance of all buildings and increase the competence of those working across the built environment.

The Building Safety Regulator was established in shadow form in January 2020, and it is intended that the new regime will come fully into force in April 2024, with interim steps, such as requiring accountable people to register their buildings, coming in the meantime. Residents can be confident that their safety is a critical objective of the new regulator. The regime also introduces new oversight requirements during the build phase. This means that before proceeding to the next stage, the developer must satisfy the Building Safety Regulator that they have met the relevant requirements in the building regulations. Between these stages, the Building Safety Regulator can carry out on-site inspections or request information about the building work.

On planning, our policy and decisions should promote an effective use of land in meeting the need for homes and other uses, while safeguarding and improving the environment and ensuring safe and healthy living conditions. Through reforming the planning system, we will champion how beautiful design can enhance health and wellbeing, and encourage sustainable development accompanied by infrastructure that communities will truly benefit from. Building more homes is a fundamental task for the Government and local leaders. The measures we are already delivering—for example, those set out in the Levelling-up and Regeneration Bill—are a significant step in improving the way planning operates, but we want to go further in specific areas of potential through investment zones, for example, to deliver the attractive, well-designed new communities we all want to see.

[Jim Shannon]

I am pleased by the Minister’s comprehensive response; it is very helpful. I will ask two questions. I said in my speech that landlords need to be incentivised, if there is a methodology to make that happen, to improve their homes. I appreciate what will happen going forward, but we have so many homes in the United Kingdom—18.5 million—that need to be retrofitted. I am ever mindful that this issue crosses different Departments and may not be the direct responsibility of the Minister when it comes to skills and a national training scheme.

The hon. Member for St Ives (Derek Thomas) could not be here today because he had to return to his constituency. He said to me the other day that those who are in construction are getting older, and as they get older we need a new group of young workers coming through who have the skills to retrofit. Those are two questions. I am not sure if they are the direct responsibility of the Minister, but I know that he will deliver them to the person who has that responsibility.

--- Later in debate ---

[Andrew Stephenson]

I thank the hon. Member for that important point. It is not directly my responsibility, but it is the kind of thing that we must work to address collectively across Government.

In a former role, I was the Minister with responsibility for construction, and we looked at the contribution that modern methods of construction and off-site construction can deliver, both in speeding up the delivery of the extra new, nice affordable homes for families that we need, and in freeing up skilled labourers to retrofit the older housing stock and to do some of the other work that we need to be done, because skills are in short supply. It is therefore important that we have a solid skills strategy. That is something that my Department and Ministers in BEIS are particularly keen to look at and work together on to ensure that we have a consistent approach that helps to deliver what we both want to see in this area.

Turning to one of the final areas, design and placemaking, the Government seek to ensure that new homes and places are designed to support the health and wellbeing of residents and communities. The national planning policy framework, which local planning authorities must adhere to as a matter of law, is clear that planning policies and decisions should aim to achieve healthy, inclusive and safe places. Those should support healthy lifestyles, especially where that would address identified local health and wellbeing needs. That could be through the provision of safe and accessible green infrastructure, local shops, and layouts that encourage walking and cycling.

The framework also refers to the nationally described space standard. That means that local councils have the option to set minimum space standards for new homes within their areas. The national model design code asks that local councils give consideration to the internal layouts within new homes, aiming to maximise access to natural daylight.

Through the Levelling-up and Regeneration Bill, we are introducing a duty for all local councils to produce a design code at the spatial scale of their authority area. The measure will empower communities to have their say on what their area will look like through working with local planning authorities and neighbourhood planning groups to set clear design standards through design codes. We have also set up the Office for Place within the Department for Levelling Up, Housing and Communities, which will support councils and communities to turn their vision of what they like into local standards that all new developments should meet, helping to create beautiful, healthy, successful and enduring places.

I thank all hon. Members for their contributions, and particularly the hon. Member for Strangford for securing today’s important debate. There is a huge amount of consensus from all parties on the need to address the issues that have been highlighted today. I speak not just for my Department but for the wider Government in reiterating our commitment to building the sustainable green homes and communities of the future. That is a vision that I know is shared by all.

[Jim Shannon]

Will the Minister give way before he sits down?

[Andrew Stephenson]

Certainly.

[Jim Shannon]

I make these interventions in a constructive fashion, because I want to have the answers—I think we all do; that is why we are asking. So far, the Minister has done brilliantly. I understand that 75% of new homes are not thermally efficient. Will the Minister confirm that that is the case, and say what steps will be taken to change that? The reason I ask the question is simply that it all links into the energy crisis, which has become a fact of life for all of us. I say that in a very constructive fashion. I am not trying to catch the Minister out—that is not my purpose. I would just like a wee bit of clarity on that matter.

[Andrew Stephenson]

I do not have the exact statistics to hand, but, as I said in my remarks, we are working on updating building regulations and standards. Putting energy efficiency at the heart of those standards is an important priority. This is something that my ministerial colleague in the Department leads on, but I will ensure that the hon. Member’s views are fed back to him and taken into account in our discussions.

We all realise that the challenges identified by the APPG are real, and they are priorities that the Government will address. I am keen to continue to work with the hon. Gentleman, his colleagues in the APPG and others across the House to address those challenges. Even if I am not in this role in a few weeks’ time, I am sure that my successor would be delighted to continue working with them. These are real challenges that are recognised across Government; I know that myself and my current ministerial colleagues are very keen to see them addressed.

Transport

Debate between Jim Shannon and Andrew Stephenson

Thursday 19th May 2022 Commons Chamber

[Jim Shannon (Strangford) (DUP)]

On air connectivity, yesterday at a Hospitality Ulster event it became very clear that there is a problem with connectivity between Belfast City Airport and Heathrow, not because the flights are not there but because the staffing is not there. It is trying to recruit, but is unable to do so. Will the Minister have discussions with Heathrow on solving that problem, and therefore increasing and improving air connectivity?

[Andrew Stephenson]

I thank the hon. Gentleman for his question. That issue is close to my heart, as someone who frequently flies to Northern Ireland and passes through City airport. Reducing delays at all airports across the UK is something that the aviation Minister, the Under-Secretary of State for Transport, my hon. Friend the Member for Witney (Robert Courts), is working on. I will ensure that the hon. Gentleman’s remarks are brought to his attention and we will see what more we can do to ensure that passengers are not unduly inconvenienced when passing through that airport.

We are getting on with investing more money in our railway infrastructure than any Government have invested since they were built and that is why we are making funds available to local decision makers to restore railway lines, introduce cycle lanes and fix potholes. It is why we are carrying out reforms to make our trains and buses deliver consistent value for passengers. And it is why, from self-driving vehicles to micro-mobility to zero-emissions aviation and shipping, we are laying the groundwork and preparing today for the jobs and travel habits of tomorrow.